Research programme: PPAR modulators - GlaxoSmithKline
Alternative Names: GSK3787; GW 0742; PPAR agonists research programme - GlaxoSmithKline; PPARpan; Research programme: PPARpan agonists - GlaxoSmithKlineLatest Information Update: 16 Jul 2016
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Piperazines
- Mechanism of Action Peroxisome proliferator-activated receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Cancer; Diabetes mellitus; Lipid metabolism disorders; Metabolic syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA